Skip to main content
. Author manuscript; available in PMC: 2024 Feb 13.
Published in final edited form as: Cancer Cell. 2023 Feb 13;41(2):340–355.e6. doi: 10.1016/j.ccell.2023.01.007

Figure 5. CD70 upregulation is an early event in the evolution of EGFR TKI resistance.

Figure 5.

(A-C) Western blotting of HCC4006 (A), HCC827 (B), and H1975 (C) cells following treatment with osimertinib (OSI). (D & E) ZEB1 (D) and CD70 (E) RNA levels following OSI treatment (n = 3). *p < 0.05; **p < 0.001. (F & G) Protein expression by RPPA in control and DTPCs following erlotinib (ERL; F) and osimertinib treatment (OSI; G) (n = 3). (H & I) ZEB1 and CD70 RNA in osimertinib-treated DTPCs (n = 3). *p < 0.05; **p < 0.001. (J) CD70 positivity on osimertinib-derived DTPC (n = 3). *p = 0.016, HCC827; p = 0.0086, HCC4006. (K) Representative flow cytometry data for CD70 expression on H1975 DTPCs. (L) CD70 positivity on osimertinib-derived DTPC (n = 3). *p <0.0001. (M) CD70 expression in H1975 parental and DTPCs. All bars are mean ± SD. One-way ANOVA was applied for D and E; Student’s t test was applied for H, I, J, L.